Restricted accessResearch articleFirst published online 2013-03
Darunavir Is a Good Third-Line Antiretroviral Agent for HIV Type 1-Infected Patients Failing Second-Line Protease Inhibitor-Based Regimens in South India
Eleven protease mutations have been associated with reduced susceptibility to darunavir. In this study of 87 HIV-1-infected patients experiencing virological failure to second-line regimens containing protease inhibitors boosted with ritonavir (viral load >1,000 HIV RNA copies/ml), we observed a low prevalence (3%) of ≥3 darunavir resistance-associated mutations, indicating that this drug may be a good option for third-line antiretroviral therapy in southern India.
Get full access to this article
View all access options for this article.
References
1.
KumarasamyN, VenkateshKK, DevaleenolBet al.Safety, tolerability and effectiveness of generic HAART in HIV-infected children in South India. J Trop Pediatr, 2009; 55,3:155–159.
2.
WainbergMA, ZaharatosGJ, BrennerBG. Development of antiretroviral drug resistance. N Engl J Med, 2011; 365,7:637–646.
3.
KingN, Prabu-JeyabalanM, NalivaikaEet al.Structural and thermodynamic basis for the binding of TMC114, a next-generation HIV-1 protease inhibitor. J Virol, 2004; 78:12012–12021.
4.
De MeyerS, AzijnH, SurlerauxDet al.TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother, 2005; 49:2314–2321.
5.
ThompsonMA, AbergJA, CahnPet al.and the International AIDS Society-USA: Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA, 2010; 304,3:321–333.
6.
Van MarckH, DierynckI, KrausGet al.Unraveling the complex resistance pathways of darunavir using the bioinformatics resistance determination (BIRD)Antivir Ther, 2007; 12:S141.
7.
SaravananS, VidyaM, BalakrishananPet al.Evaluation of two human immunodeficiency virus-1 genotyping systems: ViroSeq 2.0 and an in-house method. J Virol Methods, 2009; 159:211–216.
8.
Los Alamos HIV databases and HIV Database Tools. www.hiv.lanl.gov/.
9.
JohnsonVA, Brun-VézinetF, ClotetBet al.Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med, 2010; 18,5:156–163.
10.
LiuTF, ShaferRW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis, 2006; 42,11:1608–1618.
11.
De MeyerSet al.Phenotypic and genotypic determinants of resistance to darunavir: Analysis of data from treatment-experienced patients in POWER 1, 2, 3 and DUET-1 and 2[Abstract 31.]Antivir Ther, 2008; 13,Suppl 3:A33.
12.
Van MarckH, DierynckI, KrausGet al.The impact of individual human immunodeficiency virus type 1 protease mutations on drug susceptibility is highly influenced by complex interactions with the background protease sequence. J Virol, 2009; 83:9512–9520.
13.
VermeirenH, Van CraenenbroeckE, AlenPet al.Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling. J Virol Methods, 2007; 145:47–55.
14.
De MeyerS, DierynckI, LathouwersEet al.Identification of mutations predictive of a diminished response to darunavir/ritonavir: Analysis of data from treatment-experienced patients in POWER 1, 2, 3, DUET-1, DUET-2. Sixth European HIV Drug Resistance Workshop–2008. Budapest, HungaryAbstract 54.
15.
ClotetB, BellosN, MolinaJMet al.Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: A pooled subgroup analysis of data from two randomised trials. Lancet, 2007; 369:1169–1178.
16.
HillA, MoyleG. Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials. HIV Med, 2007; 8:259–264.
17.
MadrugaJV, BergerD, McMurchieMet al.Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: A randomised controlled phase III trial. Lancet, 2007; 370:49–58.
